Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1611207
PUBLISHER: Grand View Research | PRODUCT CODE: 1611207
Tumor Necrosis Factor Inhibitor Drugs Market Size, Share & Trends Analysis Report By Product (Humira, Enbrel Remicade, Simponi/Simponi Aria, Cimzia), By Application, By Sales Channel, By Region, And Segment Forecasts, 2025 - 2030
PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Tumor Necrosis Factor Inhibitor Drugs Market Growth & Trends:
The global tumor necrosis factor inhibitor drugs market size is estimated to reach USD 26.6 billion by 2030, registering a CAGR of 2.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing prevalence of autoimmune diseases, rapid technological advancements, and rise in healthcare expenditure across the globe are some of the major factors expected to drive the growth.
Currently, there are five approved TNF inhibitor drugs in the market- Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), Simponi/Simponi Aria (golimumab), and Cimzia (certolizumab). Biosimilar versions of Humira, Enbrel, and Remicade have been launched, causing a significant paradigm shift in the market.
The wave of biosimilars pose a significant internal threat to the biologics sale as biosimilars have a comparable efficiency as the original products. The cost-effectiveness of biosimilars makes them an attractive choice in economically sensitive areas. In addition, emerging countries, such as India, China, and South Korea are active participants in the biosimilar market.
Some of the key therapeutic areas involving treatment with TNF inhibitor drugs are rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Although these medicines are mostly used for the treatment of autoimmune diseases, several ongoing studies are investigating the role of TNF inhibitors in the treatment of cancer and other inflammatory conditions.
Some of the key players in the TNF inhibitor space are involved in strategic initiatives, such as mergers and acquisitions and joint ventures for the co-development of products. In addition, patent infringement issues between the manufacturers makes the market dynamics intensely competitive. For instance, AbbVie resolved an issue with Boehringer Ingelheim, regarding Humira's intellectual property (IP) rights. As per the terms of the agreement, Boehringer Ingelheim received a non-exclusive license to Humira's IP in the U.S.- scheduled to begin in July 2023.
Tumor Necrosis Factor Inhibitor Drugs Market Report Highlights:
- By product, the humira segment dominating the market with the largest revenue share of 40.5% in 2024, due to its proven effectiveness in treating various autoimmune disorders, which fostered strong trust among patients and healthcare providers.
- In 2024, Rheumatoid arthritis dominated the market and accounted for the largest revenue share of 17.51%, due to its high prevalence globally.
- The online pharmacy is expected to grow at the highest CAGR over the forecasted period, due to easy access to digital platforms, smooth ordering, in time delivery, and affordable pricing.
Product Code: GVR-3-68038-150-4
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Tumor Necrosis Factor Inhibitor Drugs Market Variables, Trends, & Scope
- 3.1. Market Introduction/Lineage Outlook
- 3.2. Market Size and Growth Prospects (USD Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
- 3.4. Tumor Necrosis Factor Inhibitor Drugs Market Analysis Tools
- 3.4.1. Porter's Analysis
- 3.4.1.1. Bargaining power of the suppliers
- 3.4.1.2. Bargaining power of the buyers
- 3.4.1.3. Threats of substitution
- 3.4.1.4. Threats from new entrants
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Economic and Social landscape
- 3.4.2.3. Technological landscape
- 3.4.2.4. Environmental landscape
- 3.4.2.5. Legal landscape
- 3.4.1. Porter's Analysis
Chapter 4. Tumor Necrosis Factor Inhibitor Drugs Market: Product Estimates & Trend Analysis
- 4.1. Type Market Share, 2024 & 2030
- 4.2. Type Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
- 4.4. Humira
- 4.4.1. Humira Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.5. Enbrel
- 4.5.1. Enbrel Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.6. Remicade
- 4.6.1 Remicade Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.7. Simponi/Simponi Aria
- 4.7.1 Simponi/Simponi Aria Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.8. Cimzia
- 4.8.1 Cimzia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.9. Biosimilars
- 4.9.1 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Tumor Necrosis Factor Inhibitor Drugs Market: Application Estimates & Trend Analysis
- 5.1. Application Market Share, 2024 & 2030
- 5.2. Application Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
- 5.4. Rheumatoid Arthritis
- 5.4.1. Rheumatoid Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5. Psoriasis
- 5.5.1. Psoriasis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6. Psoriatic Arthritis
- 5.6.1. Psoriatic Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.7. Crohn's Disease
- 5.7.1. Crohn's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.8. Ulcerative Colitis
- 5.9. Ulcerative Colitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) Psoriatic Arthritis
- 5.10. Ankylosing Spondylitis
- 5.10.1. Ankylosing Spondylitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.11. Juvenile Idiopathic Arthritis
- 5.11.1. Juvenile Idiopathic Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.12. Hidradenitis suppurativa
- 5.12.1. Hidradenitis suppurativa Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.13. Others
- 5.13.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Tumor Necrosis Factor Inhibitor Drugs Market: Sales Channel Estimates & Trend Analysis
- 6.1. Sales Channel Market Share, 2024 & 2030
- 6.2. Sales Channel Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million)
- 6.4. Hospital Pharmacy
- 6.4.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5. Speciality Pharmacy
- 6.5.1. Speciality Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6. Online Pharmacy
- 6.6.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Tumor Necrosis Factor Inhibitor Drugs Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
- 7.4. North America
- 7.4.1. North America Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Regulatory Framework
- 7.4.2.3. Competitive Insights
- 7.4.2.4. U.S. Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Regulatory Framework
- 7.4.3.3. Competitive Insights
- 7.4.3.4. Canada Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Regulatory Framework
- 7.4.4.3. Competitive Insights
- 7.4.4.4. Mexico Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5. Europe
- 7.5.1. Europe Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Regulatory Framework
- 7.5.2.3. Competitive Insights
- 7.5.2.4. UK Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Regulatory Framework
- 7.5.3.3. Competitive Insights
- 7.5.3.4. Germany Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Regulatory Framework
- 7.5.4.3. Competitive Insights
- 7.5.4.4. France Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Regulatory Framework
- 7.5.5.3. Competitive Insights
- 7.5.5.4. Italy Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Regulatory Framework
- 7.5.6.3. Competitive Insights
- 7.5.6.4. Spain Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Regulatory Framework
- 7.5.7.3. Competitive Insights
- 7.5.7.4. Denmark Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Regulatory Framework
- 7.5.8.3. Competitive Insights
- 7.5.8.4. Sweden Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Regulatory Framework
- 7.5.9.3. Competitive Insights
- 7.5.9.4. Norway Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. China
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Regulatory Framework
- 7.6.2.3. Competitive Insights
- 7.6.2.4. China Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. Japan
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Regulatory Framework
- 7.6.3.3. Competitive Insights
- 7.6.3.4. Japan Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Regulatory Framework
- 7.6.4.3. Competitive Insights
- 7.6.4.4. India Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. South Korea
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Regulatory Framework
- 7.6.5.3. Competitive Insights
- 7.6.5.4. South Korea Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.6. Australia
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Regulatory Framework
- 7.6.6.3. Competitive Insights
- 7.6.6.4. Australia Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Regulatory Framework
- 7.6.7.3. Competitive Insights
- 7.6.7.4. Thailand Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Regulatory Framework
- 7.7.2.3. Competitive Insights
- 7.7.2.4. Brazil Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Regulatory Framework
- 7.7.3.3. Competitive Insights
- 7.7.3.4. Argentina Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Regulatory Framework
- 7.8.2.3. Competitive Insights
- 7.8.2.4. South Africa Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Regulatory Framework
- 7.8.3.3. Competitive Insights
- 7.8.3.4. Saudi Arabia Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Regulatory Framework
- 7.8.4.3. Competitive Insights
- 7.8.4.4. UAE Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. AbbVie, Inc.
- 8.5.1.1. Participant's Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Recent Developments/ Strategic Initiatives
- 8.5.2. Amgen, Inc.
- 8.5.2.1. Participant's Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Recent Developments/ Strategic Initiatives
- 8.5.3. Johnson & Johnson Services, Inc.
- 8.5.3.1. Participant's Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Recent Developments/ Strategic Initiatives
- 8.5.4. UCB S.A.
- 8.5.4.1. Participant's Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Recent Developments/ Strategic Initiatives
- 8.5.5. Pfizer, Inc.
- 8.5.5.1. Participant's Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Recent Developments/ Strategic Initiatives
- 8.5.6. Novartis International AG
- 8.5.6.1. Participant's Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Recent Developments/ Strategic Initiatives
- 8.5.7. Boehringer Ingelheim Pharmaceuticals, Inc.
- 8.5.7.1. Participant's Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Recent Developments/ Strategic Initiatives
- 8.5.8. Merck & Co., Inc.
- 8.5.8.1. Participant's Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Product Benchmarking
- 8.5.8.4. Recent Developments/ Strategic Initiatives
- 8.5.1. AbbVie, Inc.
Product Code: GVR-3-68038-150-4
List of Tables
- Table 1 List of secondary sources
- Table 2 List of abbreviations
- Table 3 Global Tumor Necrosis Factor Inhibitor Drugs Market , by Region, 2018 - 2030 (USD Million)
- Table 4 Global Tumor Necrosis Factor Inhibitor Drugs Market , by Product, 2018 - 2030 (USD Million)
- Table 5 Global Tumor Necrosis Factor Inhibitor Drugs Market , by Application, 2018 - 2030 (USD Million)
- Table 6 Global Tumor Necrosis Factor Inhibitor Drugs Market , by Sales Channel, 2018 - 2030 (USD Million)
- Table 7 North America Tumor Necrosis Factor Inhibitor Drugs Market, by Country, 2018 - 2030 (USD Million)
- Table 8 North America Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
- Table 9 North America Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
- Table 10 North America Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
- Table 11 U.S. Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
- Table 12 U.S. Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
- Table 13 U.S. Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
- Table 14 Canada Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
- Table 15 Canada Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
- Table 16 Canada Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
- Table 17 Europe Tumor Necrosis Factor Inhibitor Drugs Market, by Country, 2018 - 2030 (USD Million)
- Table 18 Europe Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
- Table 19 Europe Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
- Table 20 Europe Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
- Table 21 UK Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
- Table 22 UK Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
- Table 23 UK Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
- Table 24 Germany Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
- Table 25 Germany Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
- Table 26 Germany Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
- Table 27 France Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
- Table 28 France Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
- Table 29 France Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
- Table 30 Italy Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
- Table 31 Italy Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
- Table 32 Italy Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
- Table 33 Spain Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
- Table 34 Spain Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
- Table 35 Spain Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
- Table 36 Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market, by Country, 2018 - 2030 (USD Million)
- Table 37 Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
- Table 38 Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
- Table 39 Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
- Table 40 Japan Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
- Table 41 Japan Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
- Table 42 Japan Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
- Table 43 China Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
- Table 44 China Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
- Table 45 China Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
- Table 46 Latin America Tumor Necrosis Factor Inhibitor Drugs Market, by Country, 2018 - 2030 (USD Million)
- Table 47 Latin America Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
- Table 48 Latin America Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
- Table 49 Latin America Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
- Table 50 Brazil Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
- Table 51 Brazil Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
- Table 52 Brazil Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
- Table 53 Argentina Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
- Table 54 Argentina Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
- Table 55 Argentina Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
- Table 56 Middle East & Africa Tumor Necrosis Factor Inhibitor Drugs Market, by Country, 2018 - 2030 (USD Million)
- Table 57 Middle East & Africa Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
- Table 58 Middle East & Africa Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
- Table 59 Middle East & Africa Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
- Table 60 South Africa Tumor Necrosis Factor Inhibitor Drugs Market, by Product, 2018 - 2030 (USD Million)
- Table 61 South Africa Tumor Necrosis Factor Inhibitor Drugs Market, by Application, 2018 - 2030 (USD Million)
- Table 62 South Africa Tumor Necrosis Factor Inhibitor Drugs Market, by Sales Channel, 2018 - 2030 (USD Million)
List of Figures
- Fig. 1 Tumor necrosis factor inhibitor drugs market segmentation
- Fig. 2 Market research process
- Fig. 3 Data triangulation techniques
- Fig. 4 Primary research pattern
- Fig. 5 Market research approaches
- Fig. 6 Value-chain-based sizing & forecasting
- Fig. 7 Market formulation & validation
- Fig. 8 Market snapshot
- Fig. 9 Segment outlook (USD Million)
- Fig. 10 Competitive landscape
- Fig. 11 Tumor Necrosis Factor Inhibitor Drugs Market dynamics
- Fig. 12 Tumor Necrosis Factor Inhibitor Drugs Market: Porter's five forces analysis
- Fig. 13 Tumor Necrosis Factor Inhibitor Drugs Market: PESTLE analysis
- Fig. 14 Tumor Necrosis Factor Inhibitor Drugs Market: Type segment dashboard
- Fig. 15 Tumor Necrosis Factor Inhibitor Drugs Market: Product market share analysis, 2024 & 2030
- Fig. 16 Enbrel Market, 2018 - 2030 (USD Million)
- Fig. 17 Remicade Market, 2018 - 2030 (USD Million)
- Fig. 18 Simponi/Simponi Aria Market 2018 - 2030 (USD Million)
- Fig. 19 Cimzia 2018 - 2030 (USD Million)
- Fig. 20 Biosimilars 2018 - 2030 (USD Million)
- Fig. 21 Simponi/Simponi Aria market, Cimzia Biosimilars 2018 - 2030 (USD Million)
- Fig. 22 Tumor Necrosis Factor Inhibitor Drugs Market: Application segment dashboard
- Fig. 23 Tumor Necrosis Factor Inhibitor Drugs Market: Application market share analysis, 2024 & 2030
- Fig. 24 Rheumatoid Arthritis Market 2018 - 2030 (USD Million)
- Fig. 25 Psoriasis Market, 2018 - 2030 (USD Million)
- Fig. 26 Psoriatic Arthritis Market, 2018 - 2030 (USD Million)
- Fig. 27 Ankylosing Spondylitis, 2018 - 2030 (USD Million)
- Fig. 28 Juvenile Idiopathic Arthritis Market, 2018 - 2030 (USD Million)
- Fig. 29 Hidradenitis suppurativa Market, 2018 - 2030 (USD Million)
- Fig. 30 Crohn's Disease Market, 2018 - 2030 (USD Million)
- Fig. 31 Others Market, 2018 - 2030 (USD Million)
- Fig. 32 Tumor Necrosis Factor Inhibitor Drugs Market: Sales Channel segment dashboard
- Fig. 33 Tumor Necrosis Factor Inhibitor Drugs Market: Sales Channel market share analysis, 2024 & 2030
- Fig. 34 Hospital Pharmacy Market, 2018 - 2030 (USD Million)
- Fig. 35 Speciality Pharmacy Market, 2018 - 2030 (USD Million)
- Fig. 36 Online Pharmacy Market, 2018 - 2030 (USD Million)
- Fig. 37 Tumor Necrosis Factor Inhibitor Drugs Market revenue, by Region
- Fig. 38 Regional Marketplace: Key takeaways
- Fig. 39 North America Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
- Fig. 40 U.S. country dynamics
- Fig. 41 U.S. Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
- Fig. 42 Canada country dynamics
- Fig. 43 Canada Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
- Fig. 44 Europe Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
- Fig. 45 UK country dynamics
- Fig. 46 UK Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
- Fig. 47 Germany country dynamics
- Fig. 48 Germany Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
- Fig. 49 France country dynamics
- Fig. 50 France Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
- Fig. 51 Italy country dynamics
- Fig. 52 Italy Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
- Fig. 53 Spain country dynamics
- Fig. 54 Spain Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
- Fig. 55 Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
- Fig. 56 Japan country dynamics
- Fig. 57 Japan Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
- Fig. 58 China country dynamics
- Fig. 59 China Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
- Fig. 60 Latin America Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
- Fig. 61 Brazil country dynamics
- Fig. 62 Brazil Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
- Fig. 63 Argentina country dynamics
- Fig. 64 Argentina Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
- Fig. 65 MEA Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
- Fig. 66 South Africa country dynamics
- Fig. 67 South Africa Tumor Necrosis Factor Inhibitor Drugs Market, 2018 - 2030 (USD Million)
- Fig. 68 Company categorization
- Fig. 69 Company market position analysis
- Fig. 70 Strategic framework
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.